ArticleCureus2026
Large Interstitial Pregnancy Treated With Methotrexate: A Case Report and Literature Review.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interstitial pregnancy (IP) is an ectopic pregnancy in the segment of the fallopian tube within the muscular wall of the uterus. Due to its rarity, the applicability and safety of systemic methotrexate (MTX) administration for IP remain unclear, especially when the mass is relatively large. We encountered a 21-year-old patient who was diagnosed with an asymptomatic IP of 42 mm × 52 mm and beta-human chorionic gonadotropin (β-hCG) of 7,640 mIU/ml. A single dose of systemic MTX at 50 mg/m2 gradually decreased her β-hCG levels, which became undetectable 161 days after treatment; however, the remnant mass persisted. On further follow-up, the mass disappeared 21 months after MTX administration. Our clinical experience suggests that MTX can be considered for large IPs (>4 cm) if the patient is asymptomatic and hemodynamically stable, and that remnant tissue should be recognized as an unignorable complication of MTX treatment for IPs requiring long-term follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.